Why Nkarta, Inc.’s (NKTX) Stock Is Up 6.61%
As of Monday, July 27, Nkarta, Inc.’s NKTX share price has surged by 6.61%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Commentary & Analysis
Why Nkarta, Inc.’s (NKTX) Stock Is Down 9.49%
As of Friday, July 10, Nkarta, Inc.’s NKTX share price has dipped by 9.49%, which has investors questioning if this is right time to buy.Michael Rose
Why Nkarta, Inc.’s (NKTX) Stock Is Down 11.99%
As of Friday, July 10, Nkarta, Inc.’s NKTX share price has dipped by 11.99%, which has investors questioning if this is right time to buy.Omar Beirat
Why Nkarta, Inc.’s (NKTX) Stock Is Up 5.61%
As of Tuesday, July 07, Nkarta, Inc.’s NKTX share price has surged by 5.61%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Nkarta, Inc.’s (NKTX) Stock Is Up 7.72%
As of Thursday, July 02, Nkarta, Inc.’s NKTX share price has surged by 7.72%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $149.5 | $252.6 | 25% |
|
| Shares Out (Mil) | 74.3 | 52.3 | 57% |
|
| Institutional Ownership | 99.4% | 92.1% | 88% |
|
| Float (Mil) | 60.4 | 40.2 | 52% |
|
| Beta | 0.89 | 0.95 | 53% |
|
| Avg Daily Volume (000s) | 674 | 455 | 64% |
|
| Price Change (52-week) |
(4.1%) | 52.9% | 42% |
|
| Growth | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (2.6%) | (9.9%) | 36% |
|
| EPS (5yr) | 23.7% | 16.0% | 73 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (48.8%) | (15.6%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.363) | ($1.480) | ($1.650) | |
| Month Ago EPS | ($0.363) | ($1.480) | ($1.650) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.375) | ($1.535) | ($1.790) | |
| Year/Year Chg | (3.2%) | 5.2% | 4.1% | |
| Financials | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($100) | ($43) | 11% |
|
| EPS (TTM) | ($1.349) | ($1.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($87) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($25) | $5 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $68 | $5 | 42% |
|
| Enterprise Value (Q1) (Mil) | $64 | $180 | 18% |
|
| Valuation | NKTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.52 | 2.56 | 9% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | NKTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (23.7%) | (49.8%) | 19% |
|
| ROE | (30.1%) | (55.5%) | 20% |
|
| Liabilities to Assets | 23.2% | 30.3% | 16% |
|
| F-Score | 1 | 3 | 1% |
|
Nkarta, Inc. did not pass any screens on 7/31/2026.
